Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 181

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

Wiviott, Stephen D., Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A., McGuire, Darren K., Wilding, John PH, Gause-Nilsson, Ingrid AM, Langkilde, Anna Maria, Johansson, Peter A., Sabatine, Marc S. · 2018 · American Heart Journal

Abstract

Background: Dapagliflozin is a sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitor that reduces blood glucose in patients with type 2 diabetes mellitus (T2DM) by promoting glycosuria via inhibiting urinary glucose reabsorption. In addition to improving blood glucose control, treatment with dapagliflozin results in glucose‐induced osmotic diuresis, weight loss, and blood pressure lowering. Previous trials of SGLT‐2 inhibitors showed reductions in cardiovascular (CV) events, including CV death and hospitalization for heart failure, and ischemic events in patients with atherosclerotic cardiovascular disease (ASCVD). Research design and methods: DECLARE–TIMI 58 (NCT01730534) is a phase 3b randomized, double‐blind, placebo‐controlled trial designed to evaluate the CV safety and efficacy of dapagliflozin that has completed randomization of 17,160 patients with T2DM and a history of either established ASCVD (n = 6,971) or multiple risk factors for ASCVD (n = 10,189). Patients were randomized in a 1:1 fashion to dapagliflozin 10 mg or matching placebo. The primary safety outcome is the time to the first event of the composite of CV death, myocardial infarction, or ischemic stroke (major adverse cardiovascular events; MACEs). The co‐primary efficacy outcomes are the composite of CV death, myocardial infarction, or ischemic stroke and the composite of CV death or hospitalization for heart failure. This event‐driven trial will continue until at least 1,390 subjects have a MACE outcome, thereby providing >99% power to test for the primary outcome of safety of dapagliflozin measured by rejecting the hypothesis that the upper bound of the CI >1.3 for the primary outcome of MACE, as well as 85% power to detect a 15% relative risk reduction in MACE and an estimated 87% power to detect a 20% reduction in the composite of CV death or hospitalization for heart failure at a 1‐sided &agr; level of .0231. Conclusion: The DECLARE–TIMI 58 trial is testing the hypotheses that dapagliflozin is safe (does not increase) and may reduce the occurrence of major CV events. DECLARE–TIMI 58 is the largest study to address this question with an SGLT‐2 inhibitor in patients with T2DM and with established CV disease and without CV disease but with multiple risk factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2018.01.012

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 181

Metadata

Authors
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Bansilal, S., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P., Gause-Nilsson, I. A., Langkilde, A. M., Johansson, P. A., & Sabatine, M. S.
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2018-06
Volume
200
Pages
83-89
ISSN
0002-8703 (ISSN-L)
OpenAlex
W2790193266
Cited by
181
References
11
FWCI
20.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. https://app.cochat.ai/papers/10.1016/j.ahj.2018.01.012
The paper
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Bansilal, S., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P., Gause-Nilsson, I. A., Langkilde, A. M., Johansson, P. A., & Sabatine, M. S. (2018). The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. American Heart Journal. https://doi.org/10.1016/j.ahj.2018.01.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.